Evidence map›Paper›PMID 34992966›Full record

ArticleNeurology. Clinical practice2021

Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life Study.

Francesca Schiano di Cola, Salvatore Caratozzolo, Elisabetta Venturelli, Ubaldo Balducci, Vincenzo Sidoti, Elisa Pari, Chiara Costanzi, Alfonsina di Summa, Gabriele Johanna Sixt, Elisabetta D'Adda and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesca Schiano di ColaNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Salvatore CaratozzoloNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Elisabetta VenturelliNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Ubaldo BalducciNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Vincenzo SidotiNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Elisa PariNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Chiara CostanziNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Alfonsina di SummaNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Gabriele Johanna SixtNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Elisabetta D'AddaNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Paolo LiberiniNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Renata RaoNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.
Alessandro PadovaniNeurology Unit, Clinical and Experimental Sciences Department (FSC, SC, PL, RR, AP), University and Spedali Civili, Brescia; Neurology Unit (EV), ASST Papa Giovanni XXIII, Bergamo; Neurology Unit (UB, VS), ASST Franciacorta, P.O. Chiari; Neurology Unit (EP, CC), Ospedale di Cremona, ASST Cremona; Neurology Unit (AS, GJS), Ospedale Centrale di Bolzano, Azienda Sanitaria dell'Alto Adige; and Neurology Unit (EDA), Ospedale Maggiore di Crema, ASST Crema, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess migraine outcome after 12-month treatment with erenumab and compare patients who underwent 3-month erenumab discontinuation following the first treatment cycle with those who continued monthly administrations.

methodsThis is a multicentric observational study in patients with migraine in treatment with erenumab. After a full 12-month treatment cycle (T

resultsThirty consecutive patients were enrolled. Nineteen patients underwent treatment suspension at T

conclusionAfter treatment discontinuation, a rapid migraine worsening was found, despite the high clinical response during treatment and at retreatment, which might be secondary to an untimely interruption of a potentially disease-modifying pharmacologic intervention. Although clinical improvement was documented after retreatment, given the high frequency and degree of worsening during discontinuation, it seems plausible-even ethical-to re-evaluate current timing of discontinuation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that people with migraine discontinuing erenumab migraine prophylaxis after 12 months were more likely to have an increase in nonresponder status and migraine days than those who continued treatment.

Identifiers

PMID34992966
PMCPMC8723927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.